Your browser doesn't support javascript.
loading
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Hofman, Michael S; Emmett, Louise; Sandhu, Shahneen; Iravani, Amir; Buteau, James P; Joshua, Anthony M; Goh, Jeffrey C; Pattison, David A; Tan, Thean Hsiang; Kirkwood, Ian D; Ng, Siobhan; Francis, Roslyn J; Gedye, Craig; Rutherford, Natalie K; Weickhardt, Andrew; Scott, Andrew M; Lee, Sze-Ting; Kwan, Edmond M; Azad, Arun A; Ramdave, Shakher; Redfern, Andrew D; Macdonald, William; Guminski, Alex; Hsiao, Edward; Chua, Wei; Lin, Peter; Zhang, Alison Yan; Stockler, Martin R; Williams, Scott G; Martin, Andrew J; Davis, Ian D.
Afiliação
  • Hofman MS; Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australi
  • Emmett L; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia; Faculty of Medicine, UNSW Sydney, Sydney, NSW, Australia.
  • Sandhu S; Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australi
  • Iravani A; Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Buteau JP; Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australi
  • Joshua AM; Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia.
  • Goh JC; Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia; Queensland University of Technology, Brisbane, QLD, Australia.
  • Pattison DA; Department of Nuclear Medicine and Specialised PET Services, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia; School of Medicine, University of Queensland, Brisbane, QLD, Australia.
  • Tan TH; Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia; Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia.
  • Kirkwood ID; Department of Nuclear Medicine and PET, Royal Adelaide Hospital, Adelaide, SA, Australia; Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia.
  • Ng S; Department of Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia; Medical School, University of Western Australia, Perth, WA, Australia.
  • Francis RJ; Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia; Medical School, University of Western Australia, Perth, WA, Australia.
  • Gedye C; Department of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australia; School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
  • Rutherford NK; School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia; Department of Nuclear Medicine, Hunter New England Health, New Lambton, NSW, Australia.
  • Weickhardt A; Olivia Newton-John Cancer and Wellness Centre, Austin Health, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia.
  • Scott AM; Department of Medicine, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research In
  • Lee ST; Department of Medicine, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australia; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research In
  • Kwan EM; Department of Medical Oncology, Monash Health, Melbourne, VIC, Australia.
  • Azad AA; Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australi
  • Ramdave S; Monash Health Imaging, Monash Health, Melbourne, VIC, Australia.
  • Redfern AD; Medical School, University of Western Australia, Perth, WA, Australia; Department of Medical Oncology, Fiona Stanley Hospital, Perth, WA, Australia.
  • Macdonald W; Medical School, University of Western Australia, Perth, WA, Australia; Department of Medical Oncology, Fiona Stanley Hospital, Perth, WA, Australia; Department of Nuclear Medicine, Fiona Stanley Hospital, Perth, WA, Australia.
  • Guminski A; Department of Medical Oncology, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia.
  • Hsiao E; Department of Nuclear Medicine and PET, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia.
  • Chua W; Department of Medical Oncology, Liverpool Hospital, Sydney, NSW, Australia.
  • Lin P; Faculty of Medicine, UNSW Sydney, Sydney, NSW, Australia; Department of Nuclear Medicine and PET, Liverpool Hospital, Sydney, NSW, Australia.
  • Zhang AY; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Macquarie University Hospital, Sydney, NSW, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia.
  • Stockler MR; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia.
  • Williams SG; Prostate Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, Faculty of Medicine, The University of Melbourne, Melbourne, VIC, Australi
  • Martin AJ; Centre for Clinical Research, University of Queensland, Brisbane, QLD, Australia; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Davis ID; Monash University Eastern Health Clinical School, Melbourne, VIC, Australia; Eastern Health Department of Cancer Services, Eastern Health, Melbourne, VIC, Australia.
Lancet Oncol ; 25(1): 99-107, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38043558
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração / Radioisótopos de Gálio Limite: Humans / Male País/Região como assunto: Oceania Idioma: En Revista: Lancet Oncol Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias de Próstata Resistentes à Castração / Radioisótopos de Gálio Limite: Humans / Male País/Região como assunto: Oceania Idioma: En Revista: Lancet Oncol Ano de publicação: 2024 Tipo de documento: Article